Justin M. Watts

5.3k total citations
127 papers, 968 citations indexed

About

Justin M. Watts is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Justin M. Watts has authored 127 papers receiving a total of 968 indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Hematology, 46 papers in Genetics and 43 papers in Molecular Biology. Recurrent topics in Justin M. Watts's work include Acute Myeloid Leukemia Research (100 papers), Chronic Myeloid Leukemia Treatments (31 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (27 papers). Justin M. Watts is often cited by papers focused on Acute Myeloid Leukemia Research (100 papers), Chronic Myeloid Leukemia Treatments (31 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (27 papers). Justin M. Watts collaborates with scholars based in United States, France and Spain. Justin M. Watts's co-authors include Martin S. Tallman, Michele Stanchina, Justin Taylor, Terrence Bradley, Sangeetha Venugopal, Tara L. Lin, Fatih M. Uckun, Binbin Zheng-Lin, Christopher R. Cogle and Jörge E. Cortes and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Justin M. Watts

115 papers receiving 954 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Justin M. Watts United States 17 560 530 193 169 115 127 968
Po Yee Mak United States 16 602 1.1× 605 1.1× 205 1.1× 270 1.6× 189 1.6× 57 1.1k
YinWei Ho United States 10 608 1.1× 530 1.0× 262 1.4× 263 1.6× 96 0.8× 14 1.1k
Anand Jillella United States 12 456 0.8× 379 0.7× 166 0.9× 113 0.7× 136 1.2× 48 841
Ya‐Huei Kuo United States 15 579 1.0× 357 0.7× 235 1.2× 94 0.6× 179 1.6× 44 930
Victoria Grandage United Kingdom 9 492 0.9× 472 0.9× 177 0.9× 147 0.9× 92 0.8× 16 926
Alan Burnett United Kingdom 8 977 1.7× 856 1.6× 165 0.9× 192 1.1× 132 1.1× 14 1.4k
Patrick Hayden Ireland 19 558 1.0× 415 0.8× 346 1.8× 144 0.9× 68 0.6× 53 996
Hankui Chen United States 12 506 0.9× 423 0.8× 147 0.8× 152 0.9× 137 1.2× 22 993
Amitava Sengupta India 15 460 0.8× 237 0.4× 114 0.6× 103 0.6× 103 0.9× 38 718
N. Roubi France 6 558 1.0× 377 0.7× 232 1.2× 116 0.7× 108 0.9× 8 809

Countries citing papers authored by Justin M. Watts

Since Specialization
Citations

This map shows the geographic impact of Justin M. Watts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin M. Watts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin M. Watts more than expected).

Fields of papers citing papers by Justin M. Watts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin M. Watts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin M. Watts. The network helps show where Justin M. Watts may publish in the future.

Co-authorship network of co-authors of Justin M. Watts

This figure shows the co-authorship network connecting the top 25 collaborators of Justin M. Watts. A scholar is included among the top collaborators of Justin M. Watts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin M. Watts. Justin M. Watts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Malig, Maika, Olga Sala‐Torra, Mary Wood, et al.. (2024). Genomic Proximity Mapping (GPM): Evaluation of a Next Generation Cytogenomic Assay for Improved Risk Stratification in Acute Myeloid Leukemia. Blood. 144(Supplement 1). 6157–6157. 1 indexed citations
3.
Watts, Justin M., Alessandro M. Vannucchi, Anthony M. Hunter, et al.. (2024). Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.. Journal of Clinical Oncology. 42(16_suppl). 6576–6576. 1 indexed citations
4.
Wang, Eunice S., Jörge E. Cortes, Justin M. Watts, et al.. (2024). Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib. Blood. 144(Supplement 1). 1514–1514.
5.
Watts, Justin M., Simon J. Shaw, & Brian A. Jonas. (2024). Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia. Current Treatment Options in Oncology. 25(11). 1345–1353. 7 indexed citations
6.
DiNardo, Courtney D., Gail J. Roboz, Justin M. Watts, et al.. (2024). Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Advances. 8(15). 4209–4220. 21 indexed citations
7.
DiNardo, Courtney D., Gail J. Roboz, Justin M. Watts, et al.. (2023). P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME. HemaSphere. 7(S3). e75740ab–e75740ab. 3 indexed citations
8.
Venugopal, Sangeetha & Justin M. Watts. (2023). Olutasidenib: from bench to bedside. Blood Advances. 7(16). 4358–4365. 19 indexed citations
9.
Cortes, Jörge E., et al.. (2023). P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML. HemaSphere. 7(S3). e14426d1–e14426d1. 1 indexed citations
10.
Jonas, Brian A., Jing‐Zhou Hou, Gail J. Roboz, et al.. (2023). A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological Oncology. 41(4). 743–752. 12 indexed citations
11.
Venugopal, Sangeetha & Justin M. Watts. (2023). The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy. Hematology. 2023(1). 192–197. 6 indexed citations
12.
Bewersdorf, Jan Philipp, Maximilian Stahl, Justin Taylor, et al.. (2023). E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 37(12). 2512–2516. 36 indexed citations
13.
Stanchina, Michele, et al.. (2022). Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date. Cancer Management and Research. Volume 14. 2267–2272. 11 indexed citations
14.
Uckun, Fatih M., Justin M. Watts, Alice S. Mims, et al.. (2021). Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers. 13(21). 5287–5287. 7 indexed citations
15.
Santos, Helena G. Dos, Deukwoo Kwon, Terrence Bradley, et al.. (2021). Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies. Clinical Cancer Research. 27(7). 1893–1903. 32 indexed citations
16.
Raja, Mohammed, Yoichiro Natori, José F. Camargo, et al.. (2020). Discordance Between Radiologic Findings and Molecular Testing in Patients With Underlying Hematologic Malignancy and Coronavirus Disease 2019. Open Forum Infectious Diseases. 7(9). ofaa372–ofaa372. 1 indexed citations
17.
Watts, Justin M., et al.. (2019). The Effect of Empathy on Stigma Toward Students With Substance Use Disorders in College Settings. Journal of Applied Rehabilitation Counseling. 50(4). 311–330. 4 indexed citations
18.
19.
Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452. 14 indexed citations
20.
Chapman, Jennifer R., Julia T. Geyer, Yao‐Shan Fan, et al.. (2017). Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Modern Pathology. 31(3). 429–441. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Po Yee Mak Breakdown of academic impact, for papers by YinWei Ho Breakdown of academic impact, for papers by Anand Jillella Breakdown of academic impact, for papers by Ya‐Huei Kuo Breakdown of academic impact, for papers by Victoria Grandage Breakdown of academic impact, for papers by Alan Burnett Breakdown of academic impact, for papers by Patrick Hayden Breakdown of academic impact, for papers by Hankui Chen Breakdown of academic impact, for papers by Amitava Sengupta Breakdown of academic impact, for papers by N. Roubi
Rankless by CCL
2026